SCHEMBL22985886

SCHEMBL22985886

COc1cc([C@H](O)N2CCC(N3CCOCC3)CC2)ccc1Nc1nc(NC(C)C)c2c(Cl)c[nH]c2n1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ LRRK2 Q5S007 7/20 0.54
▸ DYRK1A Q13627 4/20 0.48
▸ ALK Q9UM73 4/20 0.44
▸ TTK P33981 3/20 0.44
▸ PTK2 Q05397 2/20 0.43
▸ INSR P06213 2/20 0.43
▸ IGF1R P08069 1/20 0.43
▸ EGFR P00533 1/20 0.41
▸ DYRK3 O43781 1/20 0.41
▸ CSNK1E P49674 1/20 0.41
▸ CLK1 P49759 1/20 0.41
▸ CLK2 P49760 1/20 0.41
▸ CLK3 P49761 1/20 0.41
▸ CLK4 Q9HAZ1 1/20 0.41
▸ DYRK1B Q9Y463 1/20 0.41
▸ PIK3CB P42338 1/20 0.40
▸ MAPK8 P45983 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22985894 0.92 DYRK1A (0.52) LRRK2DYRK1AALKTTKPTK2
SCHEMBL22985869 0.92 DYRK1A (0.52) LRRK2DYRK1AALKTTKPTK2
SCHEMBL22985920 0.91 LRRK2 (0.52) LRRK2DYRK1AALKTTKPTK2
SCHEMBL22985891 0.90 LRRK2 (0.53) LRRK2DYRK1AALKTTKPTK2
SCHEMBL22985862 0.89 LRRK2 (0.65) LRRK2DYRK1AALKTTKINSR
SCHEMBL22985863 0.86 ALK (0.63) LRRK2DYRK1AALKTTKPTK2
SCHEMBL18018966 0.84 LRRK2 (0.74) LRRK2DYRK1ATTKDYRK3CSNK1E
SCHEMBL22658727 0.84 LRRK2 (0.54) LRRK2DYRK1AALKTTKPTK2
SCHEMBL29409914 0.84 LRRK2 (0.54) LRRK2DYRK1AALKTTKPTK2
SCHEMBL22985893 0.79 LRRK2 (0.72) LRRK2DYRK1ATTKDYRK3CSNK1E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3778604-A1 LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME Dana Farber Cancer Institute, Inc. (US) 2021-02-17 — — EP disclosed
EP-3778605-A2 LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME Dana Farber Cancer Institute, Inc. (US) 2021-02-17 — — EP disclosed
Send feedback